Genmab AS (GMAB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $34.93 (+1.14%), Market cap $16.71B, P/E ratio 20.77, 52-week low–high $20.30 ~ $35.34.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab
Financial statements, price targets, institutional (13F) holdings and related news for Genmab AS are updated in real time on BlackAll Trade.
Genmab AS trades at $34.93 (+1.14%). Real-time quotes and charts are available on BlackAll Trade.
Genmab AS has a market cap of about $16.71B. Its P/E ratio is 20.77.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adu